Affiliation:
1. Amrita School of Pharmacy, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, 682 041, Kerala, India
2. Department of Biotechnology, Sri Shakthi Institute of Engineering and Technology, Coimbatore, 641 062, Tamil Nadu, India
3. Faculty of Pharmacy, Karpagam Academy of Higher Education, Pollachi Main Road, Coimbatore, 641 021, Tamil Nadu, India
Abstract
Abstract:
Bacopa monnieri (BM) is of immense therapeutic potential in today’s world. This review
is aimed to project the beneficial role of BM in disorders affecting the brain, including Alzheimer’s
disease, Parkinson’s disease, stroke, epilepsy, and depression. The active constituents and metabolites
responsible for the effects of BM could be bacoside A and B, bacopaside I and II, bacopasaponin C,
betulinic acid, asiatic acid, loliolide, ebelin lactone, and quercetin. The mechanistic role of BM in
brain disorders might be related to its ability to modulate neurotransmission, neurogenesis, neuronal/
glial plasticity, intracellular signaling, epigenetics, cerebral blood flow, energy metabolism,
protein folding, endoplasmic reticulum stress, neuroendocrine system, oxidative stress, inflammation,
and apoptosis. We have also discussed CDRI-08, clinical trials, safety, emerging formulation technologies,
as well as BM combinations, and dietary supplements. To propel the clinical translation of
BM in disorders affecting the brain, strategies to improve brain delivery via novel formulations and
integration of the preclinical findings into large and well-defined clinical trials, in appropriate age
groups and sex, specifically in the patient population against existing medications as well as placebo,
are essentially required.
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,General Medicine
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献